Contemporary outcomes for adults with AML requiring ICU admission.
Danielle Hammond(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Fadi Haddad(Trinity Health), Jorge Ramos Perez(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Kiyomi Morita(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Shehab Mohamed(Hamad Medical Corporation), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Alexis Geppner(The University of Texas MD Anderson Cancer Center), Yasmin Alwash(The University of Texas MD Anderson Cancer Center), Maria Siddiqui(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Daniel Rivera(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Cristina Gutiérrez(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k